- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| IMMUNOVIA Aktie jetzt für 0€ handeln | |||||
| 24.02. | Immunovia AB: Immunovia Publishes Full Year Report for 2025 | 233 | GlobeNewswire (Europe) | Highlights October-December 2025Net sales and operating results for Q4 2025 in line with expectations: Net sales of 354 KSEK for the period (455) largely reflected royalty revenue. Operating loss was... ► Artikel lesen | |
| 20.01. | Immunovia AB: The Board of Directors of Immunovia withdraws proposal for reverse share split and cancels Extraordinary General Meeting | 108 | GlobeNewswire (Europe) | Following discussions with major shareholders, the Board of Directors of Immunovia AB (publ) ("Immunovia" or the "Company") has decided to withdraw the proposal for a reverse share split and the Extraordinary... ► Artikel lesen | |
| 19.01. | Immunovia AB: Immunovia receives state regulatory approval for PancreaSure in California and initiates commercial rollout | 190 | GlobeNewswire (Europe) | Immunovia AB (IMMNOV: Nasdaq Stockholm), a pancreatic cancer diagnostics company, today announced that it has received regulatory approval for its PancreaSure test in California, US, enabling commercial... ► Artikel lesen | |
| 17.12.25 | Immunovia AB: The Board of Directors of Immunovia proposes a reverse share split | 325 | GlobeNewswire (Europe) | The Board of Directors of Immunovia AB (publ) ("Immunovia" or the "Company") proposes that an Extraordinary General Meeting on 22 January 2026 resolves to carry out a reverse share split, in the ratio... ► Artikel lesen | |
| 26.11.25 | Immunovia AB Q3 Loss Decreases | 2 | RTTNews | ||
| 26.11.25 | Immunovia: Strategiewechsel und Aktiensprung nach Q3-Zahlen | 3 | Investing.com Deutsch | ||
| 26.11.25 | Immunovia AB: Immunovia receives final Medicare payment rate for PancreaSure test | 241 | GlobeNewswire (Europe) | LUND, Sweden - Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced that the Centers for Medicare & Medicaid Services (CMS) has finalized a national payment... ► Artikel lesen | |
| 26.11.25 | Immunovia AB: Immunovia Publishes Interim Report for July-September 2025 | 252 | GlobeNewswire (Europe) | Highlights July-September 2025Net sales and operating loss for Q3 2025 in line with expectations: Net sales of 101 KSEK for the period (235) largely reflected royalty revenue. Operating loss was 25.5... ► Artikel lesen | |
| 03.10.25 | Immunovia AB: Immunovia publishes information document regarding rights issue | 502 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 01.10.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 01.10.2025 | 640 | Xetra Newsboard | Das Instrument RIHN CH0003671440 RIETER HLDG NA SF 5 EQUITY wird cum Kapitalmassnahme gehandelt am 01.10.2025 und ex Kapitalmassnahme am 02.10.2025 The instrument RIHN CH0003671440 RIETER HLDG NA SF... ► Artikel lesen | |
| 29.09.25 | Immunovia AB: Bulletin from the extraordinary general meeting in Immunovia AB (publ) | 390 | GlobeNewswire (Europe) | Today, on 29 September 2025, an extraordinary general meeting was held in Immunovia AB (publ). A summary of the adopted resolutions follows below.
Resolution on amendment of the Articles of AssociationThe... ► Artikel lesen | |
| 22.09.25 | Onconetix, Inc.: Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM | 604 | GlobeNewswire (Europe) |
CINCINNATI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) ("Onconetix" or the "Company") a commercial stage biotechnology company focused on the research, development and commercialization... ► Artikel lesen | |
| 22.09.25 | Immunovia AB: Immunovia Secures Control of PancreaSure Supply Chain and Achieves Cost Reduction through Licensing Agreement | 279 | GlobeNewswire (Europe) | LUND, Sweden - Immunovia AB (publ.), the pancreatic cancer diagnostics company, has announced the successful conclusion of an agreement to acquire assets and license intellectual property that will... ► Artikel lesen | |
| 15.09.25 | Immunovia AB: Inova Schar Cancer Adopts Immunovia's PancreaSure Test for its High-Risk Surveillance Program | 298 | GlobeNewswire (Europe) | LUND, Sweden - Immunovia (publ.), the pancreatic cancer diagnostics company, today announced that its PancreaSure test will be offered to patients in Inova Schar Cancer's high-risk surveillance program... ► Artikel lesen | |
| 08.09.25 | Immunovia AB: Immunovia enters into top guarantee commitments for the upcoming rights issue | 293 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 28.08.25 | Immunovia AB: Immunovia Publishes Interim Report for January-June 2024 | 247 | GlobeNewswire (Europe) | April-June 2025Net sales, which for the quarter only included royalties, amounted to 90 KSEK (85).Operating loss was -20.1 MSEK, down from -23.9 MSEK in the second quarter of 2024. Net earnings were... ► Artikel lesen | |
| 27.08.25 | Immunovia AB: Immunovia carries out a rights issue of approximately SEK 100 million and secures bridge loans | 539 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 19.08.25 | Immunovia AB: Immunovia set to launch PancreaSure in the US on September 2nd, shares commercial strategy | 243 | GlobeNewswire (Europe) | LUND, Sweden - Immunovia (publ.) the pancreatic cancer diagnostics company, today announced that the PancreaSure test is set to launch in the US on September 2nd. The company's initial focus will be... ► Artikel lesen | |
| 14.05.25 | Immunovia AB: Immunovia Publishes Interim Report for January-March 2025 | 324 | GlobeNewswire (Europe) | January-March 2025• Net sales, which for the quarter only included royalties, amounted to 139 KSEK (156).• Net earnings were -57.8 MSEK (-2.9), as a result of unrealized exchange rate effects due to... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HIMS & HERS HEALTH | 22,600 | -1,40 % | Hims & Hers-Aktie: Neue Chancen nach dem Hype? | Die Aktie von Hims & Hers Health hat nach einer Zeit voller Hype und überschwänglichen Erwartungen in den vergangenen Monaten massiv gelitten. Nach einem deutlichen Kursrückgang rückt nun die Frage... ► Artikel lesen | |
| BECTON DICKINSON | 131,70 | +0,19 % | Waters Corporation: Waters Announces CE Mark for Next-Generation Fully Automated BD BACTEC FXI Culture System for Bloodstream Infection Diagnosis | Achieves a ~3-hour faster time to detection (~15% reduction) versus the prior generation system, per clinical study data,¹ enabling earlier targeted therapy.First-of-its-kind blood volume... ► Artikel lesen | |
| RYMAN HEALTHCARE | 0,965 | -4,03 % | Ryman Healthcare Achieves FY26 Sales Guidance Amidst Strong Q4 Performance | ||
| SOLENO THERAPEUTICS | 44,820 | +0,40 % | Weekly Buzz: MacroGenics Resumes LINNET; GSK Wins China Nod; FDA Okays Waters Corporation; Neurocrine Biosciences Snaps Up Soleno Therapeutics | THOUSAND OAKS (dpa-AFX) - This week's biotech landscape witnessed regulatory approvals across the U.S., Canada, and China, alongside the lifting of a clinical trial hold by the FDA, collaborations... ► Artikel lesen | |
| SIENNA SENIOR LIVING | 14,200 | 0,00 % | Sienna Senior Living: Sienna Announces April Dividend | MARKHAM, Ontario, April 15, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. ("Sienna" or the "Company") (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a... ► Artikel lesen | |
| NIAGEN BIOSCIENCE | 3,800 | -5,47 % | Niagen Bioscience, Inc.: Niagen Bioscience is the Premiere Sponsor of the Inaugural "NAD for Health: Opportunities & Challenges" Conference Hosted by the University of Copenhagen | Taking place March 23-25, 2026, this three-day scientific forum will convene the world's foremost NAD experts in Copenhagen to advance evidence-based dialogue and accelerate clinical translation... ► Artikel lesen | |
| MICROPORT SCIENTIFIC | 0,970 | -2,02 % | UBS Upgrades MICROPORT MEDBOT to Buy on Strong Overseas Sales, Expects Breakeven in 1H26 | ||
| EXTENDICARE | 18,200 | 0,00 % | Extendicare Inc.: Extendicare Announces Voting Results for its 2026 Annual Meeting of Shareholders | MARKHAM, Ontario, April 16, 2026 (GLOBE NEWSWIRE) -- Extendicare Inc. ("Extendicare" or the "Company") (TSX: EXE) today announced the results of matters voted on at its annual meeting of shareholders... ► Artikel lesen | |
| VERADIGM | 7,350 | -100,00 % | Veradigm to Appoint Christian Greyenbuhl as Chief Financial Officer | ||
| NATIONAL HEALTHCARE CORPORATION | 132,00 | 0,00 % | Dividendenbekanntmachungen (31.03.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACADIA REALTY TRUST US0042391096 0,2 USD 0,1744 EUR ACADIAN TIMBER CORP CA0042721005 0,29 CAD 0,1816 EUR ADVANCED FLOWER CAPITAL... ► Artikel lesen | |
| UNIPHAR | 4,075 | +2,64 % | Uniphar executives conduct share transactions under compensation plan | ||
| HANGZHOU TIGERMED CONSULTING | 4,660 | 0,00 % | TIGERMED (03347): DATE OF BOARD MEETING | ||
| FRESENIUS MEDICAL CARE | 39,130 | +0,46 % | Shortseller-Positionen aktuell: u.a. Carl Zeiss Meditec, Evonik, FMC, Gerresheimer, GFT, MTU, Nordex, Ströer | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| BUTTERFLY NETWORK | 5,280 | +8,64 % | Butterfly Network wins FDA clearance for gestational age AI ultrasound tool | ||
| BRIGHTSPRING HEALTH SERVICES | 45,810 | 0,00 % | BrightSpring Health Services, Inc.: BrightSpring Health Services Completes Sale of ResCare Community Living to Sevita | LOUISVILLE, Ky., March 31, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. ("BrightSpring" or the "Company") (NASDAQ: BTSG), a leading provider of home and community-based pharmacy and... ► Artikel lesen |
IMMUNOVIA AB gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 0,001 Euro und damit +300,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMMUNOVIA AB finden Sie auf Wallstreet Online.